Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Brenton

Showing results (161-170 of 229) with videos related to

Pageof 23
Sort By:
Molecular Oncology|August 30, 2014
A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancerHans Kristian Moen Vollan, Oscar M Rueda, Suet-Feung Chin, et al.
Journal of Medical Genetics|May 22, 2016
New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) studyInga Plaskocinska, Hannah Shipman, James Drummond, et al.
European Radiology Experimental|December 6, 2023
Deep learning-based segmentation of multisite disease in ovarian cancerThomas Buddenkotte, Leonardo Rundo, Ramona Woitek, et al.
Gynecologic Oncology|March 23, 2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2Gottfried E Konecny, Amit M Oza, Anna V Tinker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 18, 2023
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational studyRobert D Morgan, Andrew R Clamp, Bethany M Barnes, et al.
Gynecologic Oncology|September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
Nature|April 24, 2012
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsChristina Curtis, Sohrab P Shah, Suet-Feung Chin, et al.
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
Nature Reviews. Cancer|September 24, 2011
Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Jermaine I Coward, Robert C Bast, et al.
Lancet (London, England)|December 4, 2019
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R Clamp, Elizabeth C James, Iain A McNeish, et al.
Pageof 23

Showing results (161-170 of 229) with videos related to

Sort By:
Pageof 23
Molecular Oncology|August 30, 2014
A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancerHans Kristian Moen Vollan, Oscar M Rueda, Suet-Feung Chin, et al.
Journal of Medical Genetics|May 22, 2016
New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) studyInga Plaskocinska, Hannah Shipman, James Drummond, et al.
European Radiology Experimental|December 6, 2023
Deep learning-based segmentation of multisite disease in ovarian cancerThomas Buddenkotte, Leonardo Rundo, Ramona Woitek, et al.
Gynecologic Oncology|March 23, 2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2Gottfried E Konecny, Amit M Oza, Anna V Tinker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 18, 2023
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational studyRobert D Morgan, Andrew R Clamp, Bethany M Barnes, et al.
Gynecologic Oncology|September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
Nature|April 24, 2012
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsChristina Curtis, Sohrab P Shah, Suet-Feung Chin, et al.
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
Nature Reviews. Cancer|September 24, 2011
Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Jermaine I Coward, Robert C Bast, et al.
Lancet (London, England)|December 4, 2019
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R Clamp, Elizabeth C James, Iain A McNeish, et al.
Pageof 23